10:11 AM EDT, 05/16/2024 (MT Newswires) -- Takeda Pharmaceutical's ( TAK ) Canada unit said Thursday it has completed talks with the pan-Canadian Pharmaceutical Alliance for a letter of intent to provide public access to Livtencity as a treatment for post-transplant cytomegalovirus infection resistant to prior antiviral therapies.

The company said provinces and territories can now progress with individual formulary listings, with the timing of each listing varying by province or territory.

Price: 13.29, Change: -0.10, Percent Change: -0.75